Hepatorenal Syndrome Market Report 2025

The hepatorenal syndrome market size has grown strongly in recent years. It will grow from $1.29 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be credited to factors such as higher healthcare spending, an increase in hepatitis infections, government-driven initiatives, a growing prevalence of virally-induced liver diseases, and a rise in investments in research and development.

The hepatorenal syndrome market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecast period can be attributed to factors such as the growing prevalence of liver diseases, the expansion of liver transplant programs, an increase in disease rates, a rise in cases of direct kidney injury, and a higher incidence of liver diseases. Key trends in the forecast period include the adoption of advanced technologies, enhanced government support programs, better diagnostic tools, progress in personalized medicine, and advancements in nephrology.

The growing prevalence of liver diseases is expected to drive the growth of the hepatorenal syndrome market. Liver diseases include conditions such as hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases that impair liver function. Factors such as obesity, diabetes, alcohol consumption, viral infections, poor diet, and exposure to toxins contribute to the rising incidence of liver diseases. Conditions such as cirrhosis and acute liver failure increase the risk of hepatorenal syndrome by causing significant hemodynamic and kidney dysfunction as the liver progressively deteriorates. For example, in April 2024, the Office for Health Improvement & Disparities (OHID) reported that hospital admissions in the UK for liver disease had risen to 155.2 per 100,000 people in 2023, up from 150.6 per 100,000 in 2022. This increase in liver diseases is driving the growth of the hepatorenal syndrome market.

The rise in research and development investments is expected to support the growth of the hepatorenal syndrome market. R&D investments are crucial for innovation, product development, and the creation of new technologies. These investments are driven by technological progress, market competition, healthcare needs, and demand for new solutions. In the case of hepatorenal syndrome, R&D is advancing therapies, diagnostic tools, and treatment approaches, ultimately improving patient outcomes. For example, the UK government reported a 10.5% increase in R&D spending in 2022, reaching £15.5 billion (USD 16.18 billion), up from £14 billion (USD 14.61 billion) in 2021. This rise in R&D investment is fueling the growth of the hepatorenal syndrome market.

Companies in the hepatorenal syndrome market are also focusing on developing innovative therapies that target both liver and kidney dysfunction to improve patient outcomes. One such innovation is the cytopheretic device (Cytosorb), an extracorporeal blood purification therapy that reduces systemic inflammation and immune activation in critically ill patients, including those with hepatorenal syndrome. In October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, received FDA approval for its Selective Cytopheretic Device (SCD) to treat hepatorenal syndrome. This advanced therapy focuses on hyperinflammation, a key factor in kidney dysfunction in patients with acute-on-chronic liver failure. By modulating the immune response, SCD helps regulate abnormal immune responses, supporting kidney recovery and improving the chances of liver transplant eligibility. Its effectiveness in improving organ function has been demonstrated in preclinical and clinical studies across various conditions, including sepsis, acute kidney injury (AKI), and cardiorenal syndrome.

Major players in the hepatorenal syndrome market are Eli Lilly and Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd, Baxter International Inc., Ferring Pharmaceuticals Ltd, Mallinckrodt Pharmaceuticals, Zentiva k.s, Hybio Pharmaceutical Co. Ltd, Cumberland Pharmaceuticals Inc., La Jolla Pharmaceutical Company, Innoviva Specialty Therapeutics Inc, SeaStar Medical, New Medicon Pharma Lab, Orphan Therapeutics LLC, BioVie Inc., Noorik Biopharmaceuticals, Ocelot Bio Inc., Ikaria Inc, PharmaIN Corp, and ESP Pharma Inc.

North America was the largest region in the hepatorenal syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatorenal syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepatorenal syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hepatorenal syndrome (HRS) is a serious complication that occurs in advanced liver disease, leading to functional kidney failure due to reduced blood flow to the kidneys, despite no structural damage. It results from splanchnic vasodilation, which triggers renal vasoconstriction and a reduction in glomerular filtration.

The primary types of hepatorenal syndrome include type 1, type 2, and other variations. Type 1 hepatorenal syndrome is a rapidly worsening kidney failure in individuals with severe liver disease, marked by a rapid decline in kidney function over a period of days to weeks. Treatment options for type 1 HRS include liver transplantation, terlipressin, albumin infusion, hemodialysis, vasoconstrictors, and antibiotics. To diagnose HRS, tests such as a complete blood count, liver function tests, urinalysis, and urine electrolytes are performed. It is available through hospital pharmacies, online pharmacies, retail pharmacies, and other outlets. The primary consumers include hospitals, home care services, specialty clinics, and other healthcare facilities.

The hepatorenal syndrome market research report is one of a series of new reports that provides hepatorenal syndrome market statistics, including the hepatorenal syndrome industry global market size, regional shares, competitors with the hepatorenal syndrome market share, detailed hepatorenal syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatorenal syndrome industry. This hepatorenal syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hepatorenal syndrome market consists of revenues earned by entities by providing services such as medical management services, dialysis services, and liver transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatorenal syndrome market also includes sales of angiotensin, dialysis products, and continuous renal replacement therapy (CRRT) machines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.